Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Optimum use of tacrolimus in the prophylaxis of graft versus host disease
Autore:
Uberti, JP; Cronin, S; Ratanatharathorn, V;
Indirizzi:
Univplantatan, Med Ctr, Canc Ctr 0914 B1207, Blood & Marrow Stem Cell Trans Univ Michigan Ann Arbor MI USA 48109 1207, Blood & Marrow Stem Cell Trans Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 nternal Med, Ann Arbor, MI 48109 USA Univ Michigan, Sch Med, Coll Pharm, Ann Arbor, MI 48109 USA Univ MichiganAnn Arbor MI USA 48109 Coll Pharm, Ann Arbor, MI 48109 USA
Titolo Testata:
BIODRUGS
fascicolo: 5, volume: 11, anno: 1999,
pagine: 343 - 358
SICI:
1173-8804(199905)11:5<343:OUOTIT>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; TERM FOLLOW-UP; LIVER ALLOGRAFT RECIPIENTS; SEVERE APLASTIC-ANEMIA; CYCLOSPORINE-A; WHOLE-BLOOD; HEMATOLOGIC MALIGNANCIES; DRUG-INTERACTIONS; FK506 TACROLIMUS; CONTROLLED TRIAL;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
71
Recensione:
Indirizzi per estratti:
Indirizzo: Ratanatharathorn, V Univplantatan, Med Ctr, Canc Ctr 0914 B1207, Blood & Marrow Stem Cell Trans Univ Michigan 1500 E Med Ctr Dr Ann Arbor MI USA 48109
Citazione:
J.P. Uberti et al., "Optimum use of tacrolimus in the prophylaxis of graft versus host disease", BIODRUGS, 11(5), 1999, pp. 343-358

Abstract

Transplantation of haemopoietic stem cells containing immunocompetent cells invariably leads to the development of graft versus host disease (GVHD) in the recipients unless immunosuppressive prophylaxis is administered for approximately 6 months. Despite the availability of immunosuppressive drugs such as cyclosporin, GVHD remains the most important cause of morbidity andmortality in haemopoietic stem recipients. Tacrolimus (FK506), a macrolidelactone isolated from the fermentation broth of Streptomyces tsukubiensis,has been introduced as an agent with greater activity than cyclosporin forGVHD prophylaxis. Several pilot studies using tacrolimus for prophylaxis of acute GVHD have shown promising results leading to 3 major pivotal trials. These studies were nonblinded randomised trials comparing the combinationof tacrolimus and methotrexate with cyclosporin and methotrexate in both matched sibling and unrelated donor transplants for the prevention of acute GVHD. All 3 trials showed a significantly lower incidence of acute GVHD in the tacrolimus arm when compared to the cyclosporin ann. The overall and disease-free survival of patients with non-advanced malignancies was similar between the 2 groups. In one matched sibling study, the overall and disease-free survival in high-risk advanced disease patients who received tacrolimus was poorer than in the cyclosporin recipients. However, a recent matchedcase controlled study using the International Bone Marrow Transplant Registry database confirmed that the poorer survival outcome of the tacrolimus recipients was due to adverse influence of baseline prognostic factors in the tacrolimus group. The toxicity profile of tacrolimus is similar to that of cyclosporin with the exception that the incidence of hirsutism and hypertension is less frequent in tacrolimus recipients. The nephrotoxicity associated with tacrolimus is dose related. Logistic regression analysis indicated that whole blood tacrolimus concentrations greater than 20 ng/ml were associated with significant nephrotoxicity. The current recommended therapeutic concentration range in whole blood is 10 to 20 ng/ml. Some studies found equal efficacy with a therapeutic range of 5 to 15 ng/ml. This review addresses many details on the practical management of adverse effects, dosage and drug interactions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 21:31:30